San Diego-based mostly Viking Therapeutics marked itself as a serious competitor within the weight loss drug industry in February immediately after revealing promising facts from the mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection and in March the